权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Comprehensive Informatics Framework for CER Dissemination

CER 传播的综合信息学框架

基本信息

批准号：
8009265
负责人：
JOSEPH E FINKELSTEIN
金额：
$ 138.68万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8009265
关键词：
Comprehensive Informatics Framework CER Dissemination

项目摘要

DESCRIPTION (provided by applicant): In this project we seek to utilize our successful experience in computer-assisted patient education in order to develop a comprehensive informatics framework for rapid adaptation and dissemination of Comparative Effectiveness Research (CER) products tailored to different categories of health consumers including difficult-to-reach patients. We will refine our current interactive education platform to implement and test a novel system for individualized continuous patient education (iCOPE). The iCOPE platform will be specifically designed to support rapid adaptation, customization, and dissemination of the CER products to the difficult-to-reach populations. The iCOPE platform will implement universal means for customized delivery of CER information in the format of interactive self-paced educational modules, quick "question & answer" guides, and interactive decision aids. In addition, the iCOPE platform will support the innovative concept of continuous patient health education by providing patients with easy access to the interactive CER updates via web, MP3 players and phone-based interactive voice response (IVR) technology. Though iCOPE will be designed to support the whole spectrum of CER products, in this project we will focus on the Comparative Effectiveness Research Summary Guide (CERSG) entitled "Pills for Type 2 Diabetes." We will assess the impact of the iCOPE platform on CERSG knowledge in a randomized clinical trial (RCT) separately in hospital, primary care and community environments. For this purpose, overall 318 elderly with diabetes will be enrolled and followed for 6 months. The comparison will be made with control group using printed versions of the CERSG. The following primary hypothesis will be tested in the RCT: Use of the iCOPE platform will be associated with improvement in CERSG knowledge in elderly at 6 month after the intervention. We will also investigate the impact of iCOPE on medication adherence, diabetes medication satisfaction, and HbA1c. The following secondary hypothesis will be evaluated: The iCOPE intervention will be associated with increase in CERSG acceptance, medication adherence self-efficacy, and positive impact on beliefs about taking diabetes medications. Cost analysis will be conducted to assess the direct costs of implementing the iCOPE intervention. PUBLIC HEALTH RELEVANCE: The aim of this study is development and evaluation of individualized continuous patient education (iCOPE) platform for adaptation and dissemination of Comparative Effectiveness Research (CER) products in difficult-to-reach populations. We will enroll 318 elderly with diabetes in a controlled clinical trial to evaluate the impact of iCOPE platform on patient knowledge of CER results, medication self-efficacy, adherence, health beliefs, and satisfaction with diabetes medications.

描述（由申请人提供）：在本项目中，我们寻求利用我们在计算机辅助患者教育方面的成功经验，以开发一个全面的信息学框架，用于快速适应和传播针对不同类别健康消费者（包括难以接触的患者）定制的比较有效性研究（CER）产品。我们将完善我们目前的互动教育平台，以实施和测试个性化持续患者教育（iCOPE）的新系统。iCOPE平台将专门设计用于支持CER产品的快速适应、定制和向难以接触的人群传播。iCOPE平台将采用通用手段，以交互式自定进度教育模块、快速“问答”指南和交互式决策辅助工具的形式，定制CER信息的交付。此外，iCOPE平台将通过网络、MP3播放器和基于电话的交互式语音应答（IVR）技术为患者提供轻松访问交互式CER更新的机会，从而支持持续患者健康教育的创新理念。虽然iCOPE将被设计为支持CER产品的整个范围，但在本项目中，我们将重点关注名为“2型糖尿病药丸”的比较有效性研究总结指南（CERSG）。“我们将在医院、初级保健和社区环境中分别进行随机临床试验（RCT），评估iCOPE平台对CERSG知识的影响。为此目的，总共将招募318名老年糖尿病患者并随访6个月。将使用印刷版CERSG与对照组进行比较。将在随机对照试验中检验以下主要假设：iCOPE平台的使用将与干预后6个月老年人CERSG知识的改善相关。我们还将研究iCOPE对药物依从性、糖尿病药物治疗满意度和HbA1c的影响。将对以下次要假设进行评价：iCOPE干预将与CERSG接受度、药物依从性自我效能以及对服用糖尿病药物的信念的积极影响的增加相关。将进行成本分析，以评估实施iCOPE干预措施的直接成本。公共卫生相关性：本研究的目的是开发和评价个体化持续患者教育（iCOPE）平台，以便在难以接触的人群中适应和传播比较有效性研究（CER）产品。我们将在一项对照临床试验中招募318名老年糖尿病患者，以评估iCOPE平台对患者CER结果知识、药物自我效能、依从性、健康信念和糖尿病药物满意度的影响。